首页 | 本学科首页   官方微博 | 高级检索  
     

莫西沙星联合头孢哌酮钠舒巴坦钠治疗老年重症肺炎的临床研究
引用本文:韩春凤,王轩. 莫西沙星联合头孢哌酮钠舒巴坦钠治疗老年重症肺炎的临床研究[J]. 中国处方药, 2021, 0(1): 87-89
作者姓名:韩春凤  王轩
作者单位:天津医科大学宝坻临床学院天津市宝坻区人民医院药剂科;天津医科大学宝坻临床学院天津市宝坻区人民医院急诊科
摘    要:
目的 探讨莫西沙星联合头孢哌酮钠舒巴坦钠治疗老年重症肺炎(SP)的应用效果.方法 回顾性选取2018年2月~2020年1月老年SP患者82例,均接受对症治疗,在此基础上接受头孢哌酮钠舒巴坦钠治疗的39例为对照组,接受莫西沙星联合头孢哌酮钠舒巴坦钠治疗的43例为研究组,比较两组疗效、康复进程(退热时间、白细胞下降时间、炎...

关 键 词:莫西沙星  重症肺炎  老年  头孢哌酮钠舒巴坦钠  病原菌清除率

Clinical study of moxifloxacin combined with cefoperazone sodium sulbactam sodium in the treatment of elderly patients with severe pneumonia
HAN Chun-feng,WANG Xuan. Clinical study of moxifloxacin combined with cefoperazone sodium sulbactam sodium in the treatment of elderly patients with severe pneumonia[J]. China Prescription Drug, 2021, 0(1): 87-89
Authors:HAN Chun-feng  WANG Xuan
Affiliation:(Department of pharmacy,Baodi district people's hospital,Baodi clinical college,Tianjin medical university,Tianjin 301800,China;不详)
Abstract:
Objective To explore the effect of moxifloxacin combined with cefoperazone sodium sulbactam sodium in the treatment of elderly patients with severe pneumonia(SP).Methods Regressively selected 82 elderly SP patients in our hospital from February 2018 to January 2020,all received symptomatic treatment,on this basis,39 cases received cefoperazone sodium sulbactam sodium as a control group,and 43 cases received moxifloxacin combined with cefoperazone sodium sulbactam sodium as a research group.Comparing the curative effect,the progress of rehabilitation(time of fever reduction,time of leukocyte decline,time of obvious absorption of inflammatory lesions),pathogen clearance,serum C-reactive protein(CRP)and procalcitonin(PCT)levels before and after treatment,and incidence of adverse reactions of the two groups.Results The total effective rate in the study group was 88.37%,significantly higher than that in the control group 66.67%(P<0.05);the time of fever reduction,time of leukocyte decline,and obvious absorption time of inflammatory lesions in the study group were significantly shorter than those in the control group(P<0.05);after treatment,the clearance rate of pathogens in the study group was 86.67%,significantly higher than that in the control group 62.50%(P<0.05);after treatment,the serum CRP and PCT levels in the study group were significantly lower than those in the control group(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Moxifloxacin combined with cefoperazone sodium sulbactam sodium is effective in the treatment of elderly patients with SP,which can improve the clearance rate of pathogenic bacteria,reduce the level of inflammatory factors in the body,promote the rehabilitation of patients,and has good safety.
Keywords:Moxifloxacin  Severe pneumonia  Elderly  Cefoperazone sodium sulbactam sodium  Pathogen clearance rate
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号